• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NMTR

    9 Meters Biopharma Inc.

    Subscribe to $NMTR
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: 9meters.com

    Peers

    $CTIC
    $CUE
    $MREO
    $RDHL
    $MTNB
    $KNTE
    $VOR
    $PNT

    Recent Analyst Ratings for 9 Meters Biopharma Inc.

    DatePrice TargetRatingAnalyst
    7/8/2021$5.00Outperform
    BMO Capital Markets
    See more ratings

    9 Meters Biopharma Inc. Financials

    Live finance-specific insights

    See more
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

      Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

      11/8/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

      Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

      8/15/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

      On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

      5/16/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021

      RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021.John Temperato, President & CEO of 9 Meters Biopharma, commented: "2021 was an exceptionally productive year for 9 Meters as we significantly advanced our pipeline, particularly our lead assets vurolenatide for short bowel syndrome (SBS) and larazotide for celiac disease. We look forward to meaningful data readouts in the second quarte

      3/23/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021

      - Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 -- Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 -- Appointed Samantha Ventimiglia of Vertex to the Board of Directors -- Quarter ending cash of $53.6 million is expected to fund operations into 2023 -RALEIGH, NC / ACCESSWIRE / November 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today provided a business update and reported financial results for the t

      11/15/21 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"

      Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Conference Call hosted by Gary Nachman and BMO Capital Markets. Please see additional details below:Biopharma Spotlight Series: Innovation in GI Conference Call Date: Thursday, August 12th, 2021Time: 11:35 am Eastern TimeTitle: DEEP DIVE ON SHORT BOWEL SYNDROME Webcast link: https://bmo.qumucloud.com/view/2021-biopharma-9metersManagement: John Temperato, President & CEO Patrick Griffin , Chief Medical Officer* a replay will be available following

      8/5/21 8:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity

      - Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) -- First planned indication is Prader-Willi Syndrome-- IND-enabling studies ongoing with first-in-human studies anticipated in 2023 -- Transaction does not impact corporate guidance and company remains fully financed into 2023 with co-lead programs' in short bowel syndrome (Phase 2) and in celiac disease (Phase 3) -RALEIGH, NC / ACCESSWIRE / July 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company has acquired global development rights to a proprietary an

      7/19/21 8:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020

      FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure  Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS  Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life  Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment  Raised over $58 million from prominent institutional healthcare investors in 2020  Research & Develop

      3/22/21 4:00:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    9 Meters Biopharma Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

      Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

      1/18/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

      RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

      1/3/22 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors

      RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Directors.Ms. Ventimiglia currently serves as Senior Vice President, U.S. Public Affairs at Vertex Pharmaceuticals, Inc., where she is responsible for developing and overseeing the company's policy, government affairs and patient advocacy strategy, including building relationships with state and federal government officials, industry organizations, patient groups and other stakeholders. Previo

      10/4/21 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors

      RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors. Mr. Rice is the president and co-founder of LifeSci Advisors, a life sciences investor relations consultancy, and the co-founder of LifeSci Capital, a research-driven investment bank. Previously, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which inc

      3/1/21 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    9 Meters Biopharma Inc. SEC Filings

    See more
    • SEC Form 25-NSE filed by 9 Meters Biopharma Inc.

      25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      9/8/23 10:11:45 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by 9 Meters Biopharma Inc.

      144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/19/23 4:41:57 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      7/18/23 8:00:11 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      6/16/23 4:26:54 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/30/23 4:11:36 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Other Events

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/22/23 8:05:44 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by 9 Meters Biopharma Inc.

      PRE 14A - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/19/23 8:07:22 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/19/23 8:02:59 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 9 Meters Biopharma Inc.

      10-Q - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/15/23 5:18:15 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      5/15/23 5:16:39 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    9 Meters Biopharma Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on 9 Meters Biopharma with a new price target

      BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00

      7/8/21 7:33:42 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 9 Meters Biopharma with a new price target

      Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00

      6/4/21 7:33:28 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital resumed coverage on 9 Meters Biopharma with a new price target

      Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00

      3/25/21 11:52:35 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on 9 Meters Biopharma with a new price target

      Oppenheimer initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $6.00

      1/29/21 6:15:21 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    9 Meters Biopharma Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/7/24 7:40:26 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/9/23 11:51:13 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 9 Meters Biopharma Inc.

      SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/8/22 4:57:05 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/1/22 5:20:37 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/10/22 10:35:05 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 9 Meters Biopharma Inc.

      SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/4/22 4:12:19 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by 9 Meters Biopharma, Inc. (Amendment)

      SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      6/28/21 5:24:24 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by 9 Meters Biopharma, Inc. (Amendment)

      SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      4/7/21 4:46:16 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by 9 Meters Biopharma, Inc.

      SC 13D/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      3/25/21 5:26:31 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    9 Meters Biopharma Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    9 Meters Biopharma Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Sensenig Bethany

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      4/21/23 5:08:33 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sirgo Mark A

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:35:29 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rice Yehuda Michael

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:28:24 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Johnson Lorin K

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:21:20 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Constantino Michael T.

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:07:09 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ventimiglia Samantha

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:01:17 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sensenig Bethany

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/29/23 4:09:52 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Temperato John

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/29/23 4:01:18 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sirgo Mark A was granted 175,000 shares, increasing direct ownership by 13% to 1,560,428 units (Amendment)

      4/A - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      7/22/22 4:21:02 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Temperato John bought $28,462 worth of shares (125,000 units at $0.23), increasing direct ownership by 10% to 1,427,522 units

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      7/8/22 8:01:02 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

      RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

      5/30/23 9:25:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

      RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

      5/15/23 5:15:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

      RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

      4/5/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022

      RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022."Our priority for 2023 remains to progress our Phase 3 vurolenatide program for short bowel syndrome including securing a clinical development and commercialization partner," commented John Temperato, President and Chief Executive Officer of 9 Meters Biopharma. "We firmly believe vurolenatide can establish a new standard of care in the treatment

      3/28/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.35 per share, are immediately exercisable, and expire three and one-half years follo

      3/15/23 4:05:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

      RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.35 per share, will b

      3/14/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

      RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.Oppenheimer 33rd Annual Healthcare ConferenceDate: Monday, March 13, 2023Time: 3:20 PM ETWebcast linkThe presentation will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.The presentation will also be available in th

      3/7/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference

      RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City.The presentation, which is accessible to registered conference attendees, will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.About 9 Meters Biopharm

      1/31/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • 9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

      Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependenceStudy design allows for the assessment of the entirety of the short bowel syndrome patient populationUS IRB approval secured; study to include up to 50 sites in North America and Europe and remains on track with study initiation as early as end-of-yearRALEIGH, NC / ACCESSWIRE / November 29, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced the design of its Phase 3 clinical trial of vurolenatide for adults with shor

      11/29/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care